CASI Pharmaceuticals (FRA:ENM) Additional Paid-In Capital : €640.80 Mil(As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Additional Paid-In Capital?

CASI Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2023 (€651.86 Mil) to Dec. 2023 (€638.04 Mil) but then increased from Dec. 2023 (€638.04 Mil) to Mar. 2024 (€640.80 Mil).

CASI Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (€616.16 Mil) to Dec. 2022 (€653.03 Mil) but then declined from Dec. 2022 (€653.03 Mil) to Dec. 2023 (€638.04 Mil).

CASI Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for CASI Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Additional Paid-In Capital Chart

CASI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

546.02

541.08

616.16

653.03

638.04

CASI Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															646.44	641.69	651.86	638.04	640.80

CASI Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

CASI Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals (FRA:ENM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CASI:USA

Address

9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines